首页 | 本学科首页   官方微博 | 高级检索  
     


Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients
Authors:Alfred Zippelius  Asma Gati  Tammo Bartnick  Senta Walton  Bernhard Odermatt  Elke Jaeger  Reinhold Dummer  Mirjana Urosevic  Valeriy Filonenko  Kazuhiro Osanai  Holger Moch  Yao-Tseng Chen  Lloyd J. Old  Alexander Knuth  Dirk Jaeger
Affiliation:1. Klinik und Poliklinik für Onkologie, Departement für Innere Medizin, Universit?tsSpital Zürich, R?mistrasse 100, 8091, Zürich, Switzerland
2. Departement für Pathologie, Universit?tsSpital Zürich, 8091, Zürich, Switzerland
3. II Medizinische Klinik, Krankenhaus Nordwest, 60488, Frankfurt, Germany
4. Dermatologische Klinik, Universit?tsSpital Zürich, 8091, Zürich, Switzerland
5. Institute of Molecular Biology and Genetics, NAS of Ukraine, 03143, Kiev, Ukraine
6. Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, 920-0293, Japan
7. Ludwig Institute for Cancer Research, New York, NY, 10148, USA
8. Weill Medical College of Cornell University, New York, NY, 10021, USA
9. Medizinische Onkologie NCT, Universit?tsklinikum Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany
Abstract:Expression pattern and immunogenicity are critical issues that define tumor antigens as diagnostic markers and potential targets for immunotherapy. The development of SEREX (serological analysis of recombinant expression libraries) has provided substantial progress in the identification of tumor antigens eliciting both cellular and humoral immune responses in cancer patients. By SEREX, we have previously identified RAB38/NY-MEL-1 as a melanocyte differentiation antigen that is highly expressed in normal melanocytes and melanoma tissues but not in other normal tissues or cancer types. In this study, we further demonstrate that RAB38/NY-MEL-1 is strongly immunogenic, leading to spontaneous antibody responses in a significant proportion of melanoma patients. The immune response occurs solely in malignant melanoma patients and was not detected in patients with other diseases, such as vitiligo, affecting melanocytes. Fine analysis of the spontaneous anti-RAB38/NY-MEL-1 antibody response reveals a polyclonal B cell recognition targeting various epitopes, although a dominant immunogenic region was preferentially recognized. Interestingly, our data indicate that this recognition is not rigid in the course of a patient’s response, as the dominant epitope changes during the disease evolution. Implications for the understanding of spontaneous humoral immune responses are discussed.Alfred Zippelius and Asma Gati contributed equally to this work.
Keywords:RAB38/NY-MEL-1  Tumor antigen  Humoral immune response  SEREX  B cell epitope  Malignant melanoma
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号